PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Promising new drug target discovered for treatment and prevention of heart failure

2012-08-27
(Press-News.org) Munich, Germany – A promising new drug target for the treatment and prevention of heart failure has been discovered by researchers at Mount Sinai School of Medicine in New York, NY, US. The study was presented at the ESC Congress 2012 by principal investigator Professor Roger J. Hajjar, MD.

According to the US Centers for Disease Control and Prevention, about 5.8 million Americans suffer from heart failure and 670,000 new cases are diagnosed each year. One in five people with heart failure die within one year of diagnosis. Heart failure is most often treated with aggressive medical and device therapy, but has no cure. The most common symptoms of heart failure are shortness of breath, feeling tired, and swelling in the ankles, feet, legs, and sometimes the abdomen.

In this study presented at the ESC Congress 2012, researchers identified a new drug target that may treat and/or prevent heart failure. The team evaluated failing human and pig hearts and discovered that SUMO1 (small ubiquitin-like modifier), a small protein that regulates the activity of key transporter genes, was decreased in failing hearts. When the researchers injected SUMO1 into these hearts via gene therapy, cardiac function was significantly improved.

"This indicates that SUMO1 may play a critical role in the pathogenesis of heart failure," said Professor Hajjar, who is research director of Mount Sinai's Wiener Family Cardiovascular Research Laboratories.

Led by Professor Hajjar, the team has been evaluating the transporter gene SERCA2a in patients with severe heart failure as part of the CUPID (Calcium Up-regulation by Percutaneous administration of gene therapy In cardiac Disease) trial. When delivered via an adeno-associated virus vector—an inactive virus that acts as a medication transporter—into cardiac cells, SERCA2a demonstrated improvement or stabilisation with minimal side effects. But Professor Hajjar said: "We found that while injection with SERCA2a restored cardiac function, over time the new SERCA2a became dysfunctional. This indicated that something else upstream from SERCA2a was causing the dysfunction in the heart."

Dr Changwon Kho, PhD, and Dr Ah Young Lee, PhD, two experts in the study of cardiac proteins at Mount Sinai School of Medicine, identified SUMO1 as the regulator of SERCA2a, showing that it enhanced its function and improved its stability and enzyme activity. When Professor Hajjar and his team studied human and animal models, they found that when SUMO1 was decreased, SERCA2a became dysfunctional in human hearts, showing that SUMO1 plays a protective role. When the team injected SUMO1 as a gene therapy, they found that it protected SERCA2a from oxidative stresses that are prevalent in heart failure.

"Our experiments over the last four years beginning with the discovery of SUMO1 as an interacting protein of SERCA2a have shown that it plays a critical role in the development of heart failure," said Professor Hajjar. "In fact, SUMO1 may be a therapeutic target at the earliest signs of development and may be beneficial in preventing its progression, a much needed advance for the millions suffering from this disease."

Dr Lisa Tilemann extended the experiments performed in mice and rats in a preclinical model of heart failure in porcine models.

Professor Hajjar said: "We have now clearly shown that SUMO1 gene delivery can enhance cardiac function and stabilize the deteriorations of left ventricular volumes in large animals with severe heart failure. We have also shown that delivering SUMO1 and SERCA2a concomitantly can have synergistic benefits on overall function in heart failure."

Led by Professor Hajjar, the Mount Sinai team discovered the landmark potential of SERCA2a in 1999 and since then has been pursuing its potential as a treatment delivered via gene therapy. The next stages in the research include testing a novel gene therapy construct which will combine both SUMO1 and SERCA2a within one gene therapy vector that will enable the investigators to express both genes simultaneously. Similar to their efforts in the CUPID trial they will explore the delivery of SERCA2a and SUMO1 via gene therapy. Additionally, the research team has developed a cellular test to screen for compounds that may increase the interaction of SERCA2a with SUMO1, evaluating SUMO1 as an adjunctive therapy to SERCA2a.

Professor Hajjar concluded: "While this study re-affirms the importance of SERCA2a as a target in heart failure, our discovery of the critical role that SUMO1 plays in improving SERCA2a function in heart failure will hopefully lead to novel treatment strategies for patients with heart failure."

### Notes to editors

The CUPID trial is funded by Celladon Corporation. The company was co-founded by Professor Hajjar who has an equity interest in Celladon Corporation and participates on an Advisory Board

Please note that picture and CV from the author, abstract, picture and CV from spokesperson can be found here. About the European Society of Cardiology www.escardio.org The European Society of Cardiology (ESC) represents more than 75,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.

About ESC Congress 2012 The ESC Congress is currently the world's premier conference on the science, management and prevention of cardiovascular disease. ESC Congress 2012 takes place 25-29 August at the Messe München in Munich. The scientific programme is available here. More information is available from the ESC Press Office at press@escardio.org.

Session details available here


ELSE PRESS RELEASES FROM THIS DATE:

Novel anti-platelet therapy reduces risk of cardiac events in patients with history of heart attack

2012-08-27
According to new research from Brigham and Women's Hospital (BWH), adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the long-term risk of recurrent cardiovascular events beyond one year in patients with a history of a prior heart attack. Researchers also identify a low-bleeding risk group among whom the clinical benefit of vorapaxar was particularly favorable. This research is presented at the European Society of Cardiology Congress 2012 and published simultaneously in the Lancet. For more than a million Americans ...

The PURE study

2012-08-27
Munich, Germany – Healthy foods such as fruits and vegetables, proteins and non-saturated fats are consumed more often by the wealthy while poorer people consume more carbohydrates, concludes a new study involving people from 17 countries. Results from the Prospective Urban Rural Epidemiology (PURE) study were reported here today by Professor Salim Yusuf of the Population Health Research Institute, McMaster University and Hamilton Health Sciences, in Hamilton, Canada and principal investigator of the study. The study, involving 154,000 individuals from 628 communities, ...

The DeFACTO study

2012-08-27
Munich, Germany – Data presented today from the prospective Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography (DeFACTO) study show that, when compared to standard coronary angiography (CT), the non-invasive assessment of fractional flow reserve by computed tomography (FFRct) provides a more accurate determination of which lesions require invasive evaluation.(1) The results of the study were presented by Dr James K. Min, director of Cardiac Imaging Research and co-director of Cardiac Imaging at the Department of Medicine, Imaging and ...

Median follow-up results from the ALTITUDE study, stopped prematurely in December 2011

2012-08-27
Munich, Germany – Preliminary results from the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) do not support administration of aliskiren on top of standard therapy with renin-angiotensin-aldosterone system (RAAS) blockade in type 2 diabetics at high risk of cardiovascular and renal events, according to Professor Hans-Henrik Parving from Rigshospitalet, University of Copenhagen, Denmark. Presenting results from the study today, he said the treatment "may even be harmful". The ALTITUDE trial was stopped prematurely in December 2011 on recommendation ...

The TRILOGY ACS study

2012-08-27
Munich, Germany – The first trial to study the effect of platelet inhibition in patients with acute coronary syndromes managed medically without revascularisation has found no significant difference between prasugrel and clopidogrel in the prevention of death, myocardial infarction or stroke. The findings, from the phase III Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) study, were presented today at a Hot Line session of ESC Congress 2012 in Munich. TRILOGY ACS was double-blind, randomised trial ...

The PARAMOUNT study

2012-08-27
Munich, Germany – The novel angiotensin receptor neprilysin inhibitor, LCZ696, demonstrated beneficial effects in heart failure patients with preserved ejection fraction (HFpEF), according to results of the PARAMOUNT (Prospective compArison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion) trial. Approximately half of all heart failure patients have normal or nearly normal ejection fraction, a measure of their strength of cardiac contraction. However, while many studies have shown a benefit of pharmacological therapies in heart failure ...

The Aldo-DHF study

2012-08-27
Munich, Germany – Mineralocorticoid receptor antagonists should be considered as a treatment option in hypertensive patients with diastolic heart failure, said Professor Burkert Pieske presenting results today of the Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) study at ESC Congress 2012. Behind his conclusion lay results showing that mineralocorticoid receptor blockade with spironolactone improves cardiac function and structure, reduces neuroendocrine activation, and effectively reduces blood pressure in a patient population with symptomatic predominantly ...

Obesity triggers AF in fertile women

2012-08-27
Munich, Germany – Obesity triggers atrial fibrillation in fertile women, according to research presented today at the ESC Congress 2012 by Dr Deniz Karasoy from Denmark. Atrial fibrillation and obesity are among the largest public health related challenges in the western world today. Atrial fibrillation is the commonest heart rhythm disorder and is associated with increased mortality and morbidity. Previous studies have demonstrated that obesity increases the risk of new-onset atrial fibrillation in individuals with known risk factors for developing atrial fibrillation ...

Female gender increases stroke risk in AF patients aged over 75 years by 20%

2012-08-27
Munich, Germany – Female gender increases the risk of stroke in patients with atrial fibrillation (AF) aged >75 years by 20%, according to a study presented today at the ESC Congress 2012. The findings were presented by Anders Mikkelsen, from Denmark. The results suggest that female gender should not be included as an independent stroke/thromboembolism (TE) risk factor in guidelines or risk stratification schemes used in treatment of patients with atrial fibrillation. The increased risk of stroke and TE in patients with atrial fibrillation depends on additional risk ...

Women with acute heart failure have similar in-hospital mortality to men but are less treated

2012-08-27
Munich, Germany – Women with acute heart failure have similar in-hospital mortality to men but are less treated in the real world, according to results from the global ALARM-HF registry presented today at the ESC Congress 2012. The findings were presented by Dr John T. Parissis from Greece. Acute heart failure (AHF) is a frequent clinical situation with high short- and long-term mortality as well as high hospitalization rates. The Acute Heart Failure Global Registry of Standard Treatment (ALARM-HF) is an in-hospital chart audit survey which includes patients hospitalized ...

LAST 30 PRESS RELEASES:

High-precision NEID spectrograph helps confirm first Gaia astrometric planet discovery

ABT-263 treatment rejuvenates aged skin and enhances wound healing

The challenge of pursuit – how saccades enable mammals to simultaneously chase prey and navigate through complex environments

Music can touch the heart, even inside the womb

Contribution of cannabis use disorder to new cases of schizophrenia has almost tripled over the past 17 years

Listening for multiple mental health disorders

Visualization of chemical phenomena in the microscopic world using semiconductor image sensor

Virus that causes COVID-19 increases risk of cardiac events

Half a degree rise in global warming will triple area of Earth too hot for humans

Identifying ED patients likely to have health-related social needs

Yo-yo dieting may significantly increase kidney disease risk in people with type 1 diabetes

Big cities fuel inequality

Financial comfort and prosociality

Painted lady butterflies migrations and genetics

Globetrotting not in the genes

Patient advocates from NCCN guidelines panels share their ‘united by unique’ stories for world cancer day

Innovative apatite nanoparticles for advancing the biocompatibility of implanted biodevices

Study debunks nuclear test misinformation following 2024 Iran earthquake

Quantum machine offers peek into “dance” of cosmic bubbles

How hungry fat cells could someday starve cancer to death

Breakthrough in childhood brain cancer research could heal treatment-resistant tumors, keep them in remission

Research discovery halts childhood brain tumor before it forms

Scientists want to throw a wrench in the gears of cancer’s growth

WSU researcher pioneers new study model with clues to anti-aging

EU awards €5 grant to 18 international researchers in critical raw materials, the “21st century's gold”

FRONTIERS launches dedicated call for early-career science journalists

Why do plants transport energy so efficiently and quickly?

AI boosts employee work experiences

Neurogenetics leader decodes trauma's imprint on the brain through groundbreaking PTSD research

High PM2.5 levels in Delhi-NCR largely independent of Punjab-Haryana crop fires

[Press-News.org] Promising new drug target discovered for treatment and prevention of heart failure